| Search by tag or site | Login to my blog ? Start my own blog |
 |
BioHealth InvestorBioHealth Investor (BHI) is a blog and journal focused on providing updated commentary and financial news from the biotech and medical technology industry. BHI's content is featured on Yahoo!Finance, Google Finance, TheStreet.com, SeekingAlpha.com and many other blogs and websites. BHI is also a proud member of The Business of Biotech Network, and the Investors Blog Network. |
Cervical Cancer Vaccine Wars Heating Up
Posted on 04/18/2007 12:48:54 | Link | Post Comment
by Jon C. Ogg
24/7 Wall St.
GlaxoSmithKline (GSK-NYSE/ADR) has just announced more positive data on its cervical cancer vaccine called CERVARIX(R). The company has said that it demonstrated 100% protection against "HPV" (Human Papillomavirus-type 16 & 18) for precancerous lesions for more than 5-years. GSK has also said that the study results also show evidence of additional protection against infections with other cancer-causing virus types.
The GSK cervical cancer candidate vaccine also showed 68 percent vaccine efficacy against precancerous lesions (CIN2+) and 38 percent vaccine efficacy against abnormal Pap smears, regardless of the type of cancer-causing virus detected. This was also effective in other forms of cancers and the study group was a double-blind, controlled trial of 1,113 young women aged 15-25 years of age. This extended follow-up study looked at study endpoints for 776 women from the same cohort of women for a period of up to 67 months in 28 centers in Brazil, Canada and the U.S.
Merck (MRK-NYSE) this morning has said that its GARDISIL(R) lasts for at least 5-years.
Both vaccines have more than enough room to be considered "blockbuster" drugs, although Merck has been the beneficiary of being the only true vaccine on market. As a reminder, at least Merck (maybe GSK too) is either conducting trials or plan to conduct trials soon to see if this can vaccinate men as well. Those test results are pretty far out from today though.
Source: 247WallSt.com
RELATED READING:
- Merck Pressured to Halt Gardasil Vaccine Lobbying
- Public Awareness Needed Before Vaccinating Girls with Merck's Gardasil
- Raggedy Ann and the Anti-Vaccination Movement
_______________________
24/7 Wall St.
GlaxoSmithKline (GSK-NYSE/ADR) has just announced more positive data on its cervical cancer vaccine called CERVARIX(R). The company has said that it demonstrated 100% protection against "HPV" (Human Papillomavirus-type 16 & 18) for precancerous lesions for more than 5-years. GSK has also said that the study results also show evidence of additional protection against infections with other cancer-causing virus types.
The GSK cervical cancer candidate vaccine also showed 68 percent vaccine efficacy against precancerous lesions (CIN2+) and 38 percent vaccine efficacy against abnormal Pap smears, regardless of the type of cancer-causing virus detected. This was also effective in other forms of cancers and the study group was a double-blind, controlled trial of 1,113 young women aged 15-25 years of age. This extended follow-up study looked at study endpoints for 776 women from the same cohort of women for a period of up to 67 months in 28 centers in Brazil, Canada and the U.S.
Merck (MRK-NYSE) this morning has said that its GARDISIL(R) lasts for at least 5-years.
Both vaccines have more than enough room to be considered "blockbuster" drugs, although Merck has been the beneficiary of being the only true vaccine on market. As a reminder, at least Merck (maybe GSK too) is either conducting trials or plan to conduct trials soon to see if this can vaccinate men as well. Those test results are pretty far out from today though.
Source: 247WallSt.com
RELATED READING:
- Merck Pressured to Halt Gardasil Vaccine Lobbying
- Public Awareness Needed Before Vaccinating Girls with Merck's Gardasil
- Raggedy Ann and the Anti-Vaccination Movement
_______________________
- Mri To Lead Growth In Medical-imaging Market
- Malaria And Hiv - Eradication And Treatment
- Dragon’s New Production Process To Cut Costs
- Mrsa Update: Cepheid, Basilea And Nektar
- If Only Us Health Care Could Be More Like The Patriots (or Even The Red Sox) And Less Like The Yankees
- The Average Joe Investor
- Wishing Wealth
- Financial Skeptic
- Edmonton Real Estate
- Don't Mess With Taxes
- Poor and Stupid
Examples
Morpheus Trading - Mon Jul 21, 2008 08:33AM
NOTE: Please click on the charts below to enlarge them if [read more]
NOTE: Please click on the charts below to enlarge them if [read more]
Morpheus Trading - Mon Jul 21, 2008 08:31AM
NOTE: Please click on the charts below to enlarge them i [read more]
NOTE: Please click on the charts below to enlarge them i [read more]
Millionaire Now! by Larry Nusbaum - Tue Jul 22, 2008 09:23AM
Hedge funds have made billions this year shorting the banks, [read more]
Hedge funds have made billions this year shorting the banks, [read more]
<< My Home | TheMoneyBlogs Home